13 results on '"Borghi, V"'
Search Results
2. LIST OF CONTRIBUTORS
- Author
-
AKCHA, F., primary, AMICHOT, M., additional, BAUMARD, P., additional, BEIRAS, R., additional, BELLOCQ, J., additional, BENVENISTE, I., additional, BERGE, J.B., additional, BISSINGER, V., additional, BOCQUENE, G., additional, BOLOGNESI, C., additional, BORGHI, V., additional, BUDZINSKI, H., additional, BURGEOT, T., additional, BURLANDO, B., additional, CLERANDEAU, C., additional, DA, SILVA DE ASSIS H.C., additional, DAUBEZE, M., additional, DE, BIASE A., additional, DE, SOUSA G., additional, DE, VALK S., additional, DEEVA, I.B., additional, DEGAN, P., additional, DEN, BESTEN P., additional, DIZER, H., additional, DONDERO, F., additional, DORONIN, Y.K., additional, DUBBELDAM, M., additional, ESCARTIN, E., additional, EVANGELISTI, V., additional, EVERAARTS, J.M., additional, GALGANI, F., additional, GARRIGUES, P., additional, GEFFARD, O., additional, GIRARD, J.P., additional, GNASSIA-BARELLI, M., additional, GORAGUER, H., additional, GUIDA, M., additional, HANSEN, P.D., additional, HIS, E., additional, IACCARINO, M., additional, KORKINA, L.G., additional, LAFAURIE, M., additional, LI, B., additional, LIVINGSTONE, D.R., additional, MELLUSO, G., additional, MERIÇ, S., additional, MORA, P., additional, MOZZONE, S., additional, NARBONNE, J.F., additional, ORAL, R., additional, PAGANO, G., additional, PETERS, L.D., additional, PORTE, C., additional, POSTMA, J.F., additional, QUINIOU, F., additional, RAHMANI, R., additional, RAOUX, C., additional, RISSO, DE FAVERNEY C., additional, ROMEO, M., additional, SABOURAULT, C., additional, SALAÜN, J.P., additional, SAVVA, D., additional, SCHOENDORF, A., additional, STIEN, X., additional, THOMPSON, S., additional, TRIEFF, N.M., additional, UNRUH, E., additional, VENIER, P., additional, VIARENGO, A., additional, VINCENT, F., additional, WALKER, C., additional, and WARNAU, M., additional
- Published
- 2001
- Full Text
- View/download PDF
3. Predictors of survival in elderly patients with coronavirus disease 2019 admitted to the hospital: derivation and validation of the FLAMINCOV score.
- Author
-
Tiseo G, Margalit I, Ripa M, Borghi V, Green H, Prendki V, Riccardi N, Dishon Y, Perego GB, Grembiale A, Galli L, Tinelli M, Castagna A, Mussini C, Yahav D, Paul M, and Falcone M
- Subjects
- Aged, Humans, Retrospective Studies, Risk Assessment, Risk Factors, Hospitals, COVID-19
- Abstract
Objective: To identify predictors of 30-day survival in elderly patients with coronavirus disease 2019 (COVID-19)., Methods: Retrospective cohort study including patients with COVID-19 aged ≥65 years hospitalized in six European sites (January 2020 to May 2021). Data on demographics, comorbidities, clinical characteristics, and outcomes were collected. A predictive score (FLAMINCOV) was developed using logistic regression. Regression coefficients were used to calculate the score. External validation was performed in a cohort including elderly patients from a major COVID-19 centre in Israel. Discrimination was evaluated using the area under the receiver operating characteristic curve (AUC) in the derivation and validation cohorts. Survival risk groups based on the score were derived and applied to the validation cohort., Results: Among 3010 patients included in the derivation cohort, 30-day survival was 74.5% (2242/3010). The intensive care unit admission rate was 7.6% (228/3010). The model predicting survival included independent functional status (OR, 4.87; 95% CI, 3.93-6.03), a oxygen saturation to fraction of inspired oxygen (SpO
2 /FiO2 ) ratio of >235 (OR, 3.75; 95% CI, 3.04-4.63), a C-reactive protein level of <14 mg/dL (OR, 2.41; 95% CI, 1.91-3.04), a creatinine level of <1.3 (OR, 2.02; 95% CI, 1.62-2.52) mg/dL, and absence of fever (OR, 1.34; 95% CI, 1.09-1.66). The score was validated in 1174 patients. The FLAMINCOV score ranges from 0 to 15 and showed good discrimination in the derivation (AUC, 0.79; 95% CI, 0.77-0.81; p < 0.001) and validation cohorts (AUC, 0.79; 95% CI, 0.76-0.81; p < 0.001). Thirty-day survival ranged from 39.4% (203/515) to 95.3% (634/665) across four risk groups according to score quartiles in the derivation cohort. Similar proportions were observed in the validation set., Discussion: The FLAMINCOV score identifying elderly with higher or lower chances of survival may allow better triage and management, including intensive care unit admission/exclusion., (Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
4. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
- Author
-
Giacomelli A, Lai A, Franzetti M, Maggiolo F, Di Giambenedetto S, Borghi V, Francisci D, Magnani G, Pecorari M, Monno L, Vicenti I, Lepore L, Lombardi F, Paolucci S, and Rusconi S
- Subjects
- Adult, Dideoxynucleosides therapeutic use, Drug Combinations, Female, Genes, Viral, HIV-1 genetics, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Lamivudine therapeutic use, Male, Middle Aged, Mutation, Oxazines, Piperazines, Pyridones, Retrospective Studies, Tenofovir therapeutic use, Viral Load, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, Drug Resistance, Viral drug effects, Drug Resistance, Viral genetics, HIV Infections drug therapy
- Abstract
The accumulation of drug-resistance mutations on combined antiretroviral regimens (ART) backbone could affect the virological efficacy of the regimen. Our aim was to assess the impact of previous drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) on the probability of virological failure (VF) in patients, under virological control, who switched to dolutegravir (DTG)+2NRTIs regimens. All HIV-1 positive drug-experienced patients who started a regimen composed by DTG+2NRTIs [abacavir/lamivudine or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)/emtricitabine (FTC)] in the ARCA collaborative group with HIV-RNA <50 cp/mL were included in the analysis. Patients with a previous VF to integrase inhibitors were excluded. The impact of single and combined NRTIs mutations on the probability of VF (defined as 2 consecutive HIV-RNA >50 copies/mL or one HIV-RNA >1000 copies/mL) was assessed by Kaplan Meier curves. A multivariable Cox regression analysis was constructed to assess factors potentially related to VF. Five hundred and eighty-eight patients were included in the analysis with a median time of viral suppression before the switch of 37 months (IQR 12-78), of whom 148 (25.2%) had at least one previous NRTIs resistance mutation. In the multivariable model no association was observed between NRTIs mutations and VF. Conversely, the duration of viral suppression before switch resulted associated with a lower risk of VF (for 1 month increase, adjusted Hazard Ratio 0.98, 95%CI 0.96-0.99; p=0.024). Previous NRTIs mutations appeared to have no impact on the risk of VF in patients switched to DTG+2NRTIs, whereas a longer interval on a controlled viremia decreased significantly the risk of VF., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
5. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients.
- Author
-
Ungaro R, Taramasso L, Bruzzone B, Vicenti I, Galli L, Borghi V, Francisci D, Pecorari M, Zoncada A, Callegaro AP, Paolini E, Monno L, Bonora S, and Di Biagio A
- Subjects
- Adolescent, Adult, Anti-HIV Agents therapeutic use, Female, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections transmission, HIV-1 drug effects, Humans, Italy epidemiology, Male, Mutation, Prevalence, Retrospective Studies, Young Adult, pol Gene Products, Human Immunodeficiency Virus genetics, Drug Resistance, Viral genetics, HIV Infections virology, HIV-1 genetics, Infectious Disease Transmission, Vertical
- Published
- 2019
- Full Text
- View/download PDF
6. Incidence of HCV infection amongst HIV positive men who had sex with men and prevalence data from patients followed at the Infectious Diseases Clinic of Modena, Italy.
- Author
-
Cuomo G, Digaetano M, Menozzi M, Tagliazucchi S, Guaraldi G, Borghi V, and Mussini C
- Subjects
- Adult, Aged, Coinfection virology, Hepatitis C Antibodies blood, Humans, Incidence, Italy epidemiology, Kaplan-Meier Estimate, Male, Middle Aged, Prevalence, Young Adult, Coinfection epidemiology, HIV Infections complications, Hepatitis C epidemiology, Homosexuality, Male statistics & numerical data
- Abstract
Background: Men who had sex with men (MSM) living with HIV are at higher risk of developing sexual transmitted diseases. This study reports two years incidence rate and prevalence of HCV in a cohort of HIV positive MSM., Methods: MSM HIV-positive outpatients negative to HCV-Ab at first observation entered a Kaplan-Meier model in order to assess the HCV infection incidence rate. Prevalence analysis was performed with MSM HIV-positive that were on follow-up at 2016. An MSM population HIV-negative served as control., Results: 421 patients entered the incidence analysis. The incidence rate of HCV infection among MSM-HIV people was 0.44 per 100 patients-years (19 events). 40 out of 442 (9%) patients were HCV-positive (prevalence analysis); they were mostly genotype 1a and 3 with APRI score <0.7 (87.5%). Univariate analysis between MSM HIV-positive patients and MSM HIV-negative showed significant differences in the prevalence rate (9.0% vs 0.6%, P < 0.001) and median age (39 vs 47, P < 0.001)., Conclusion: Incidence and prevalence rate of HCV amongst MSM HIV-positive patients is higher than in other settings. Annual HCV-Ab screening for MSM HIV-positive patients should be enforced and early treatment of HCV recommended., (Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
7. Missed treatment in an Italian HBV infected patients cohort: HBV RER.
- Author
-
Cuomo G, Borghi V, Andreone P, Massari M, Villa E, Pietrangelo A, Verucchi G, and Ferrari C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Alanine Transaminase blood, DNA, Viral blood, Databases, Factual, Female, Hepatitis B Surface Antigens blood, Hepatitis B virus genetics, Humans, Italy, Liver pathology, Logistic Models, Male, Middle Aged, Multivariate Analysis, Severity of Illness Index, Young Adult, Antiviral Agents therapeutic use, Healthcare Disparities statistics & numerical data, Hepatitis B, Chronic drug therapy
- Abstract
Background and Aims: Very little is known about the access to treatment for Chronic Hepatitis B in the real clinical practice and the characteristics of the patients who do not receive antiviral therapy., Methods: HBV-RER is an observational multicenter network that collected data of patients with HBV infection during a 3 years observational period (2009-2012)., Results: Among 2527 HBsAg positive patients, 1099 were never treated (NT); only 280 were included in the analysis due to different exclusion causes A minority was HBeAg-positive. The median age was 42. At liver biopsy most patients had Metavir score of F0-F1. Univariate analysis between 280 NT patients and the 290 naïve to treatment showed that NT patients were mostly female (P=0.002), not Italian (P=0.044), younger (P<0.001). Metavir score was lower in NT (P0.002), such as the Fib4 score (P<0.001). HBV DNA level was significantly higher in NT. At multivariate analysis, independent variables associated with no-treatment were younger age, female gender, Metavir score F0-F1, Fib4 lower than 1.6 and lower blood level of HBV-DNA., Conclusions: There is a large number of patients eligible to treatment who do not receive it. A younger age and a less severe disease seem to be associated to deferral of treatment., (Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
8. Novel genetic association of TNF-α-238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection.
- Author
-
Nasi M, Riva A, Borghi V, D'Amico R, Del Giovane C, Casoli C, Galli M, Vicenzi E, Gibellini L, De Biasi S, Clerici M, Mussini C, Cossarizza A, and Pinti M
- Subjects
- Adaptive Immunity genetics, Adult, Aged, Disease Progression, Female, Gene Frequency, Genetic Association Studies, Genetic Predisposition to Disease, HIV Infections immunology, Host-Pathogen Interactions genetics, Humans, Major Histocompatibility Complex, Male, Middle Aged, Polymorphism, Single Nucleotide, RNA, Long Noncoding, RNA, Untranslated, HIV Infections genetics, HIV-1 immunology, Programmed Cell Death 1 Receptor genetics, Tumor Necrosis Factor-alpha genetics
- Abstract
Objectives: About 2-5% of HIV-1-infected subjects, defined as long-term non-progressors (LTNPs), remain immunologically stable for a long time without treatment. The factors governing this condition are known only in part, and include genetic factors. Thus, we studied 20 polymorphisms of 15 genes encoding proinflammatory and immunoregulatory cytokines, chemokines and their receptors, genes involved in apoptosis, and the gene HCP5., Methods: We analyzed 47 Caucasian LTNPs infected for >9 years, compared with 131 HIV-1-infected Caucasian patients defined as 'usual progressors'. The genotypes were determined by methods based upon PCR, and the statistical analysis was performed by univariate logistic regression., Results: The well-known CCR5Δ32 del32 allele, the cell death-related TNF-α-238 A and PDCD1-7209 T alleles, and HCP5 rs2395029 G, a non-coding protein associated with the HLA-B*5701, were found positively associated with the LTNP condition. No association was observed for other single nucleotide polymorphisms (SDF-1-801, IL-10-592, MCP-1-2518, CX3CR1 V249I, CCR2V64I, RANTES-403, IL-2-330, IL-1β-511, IL-4-590, FASL IVS3nt-169, FAS-670, FAS-1377, FASL IVS2nt-124, PDCD1-7146, MMP-7-181, and MMP7-153)., Conclusions: The novel genetic associations between allelic variants of genes TNF-α-238 and PDCD1-7209 with the LTNP condition underline the importance of host genetic factors in the progression of HIV-1 infection and in immunological preservation., (Copyright © 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
9. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
- Author
-
Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, and Zazzi M
- Subjects
- Drug Resistance, Viral, HIV Infections drug therapy, HIV Integrase Inhibitors pharmacology, HIV Integrase Inhibitors therapeutic use, HIV-1 enzymology, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Oxazines, Piperazines, Pyridones, Raltegravir Potassium, HIV Infections virology, HIV Integrase genetics, HIV-1 genetics, Heterocyclic Compounds, 3-Ring pharmacology, Mutation, Pyrrolidinones therapeutic use
- Abstract
The prevalence of HIV-1 integrase mutations related to resistance to the next-generation integrase inhibitor (INI), dolutegravir (DTG), was assessed in 440 INI-naïve subjects and in 120 patients failing a raltegravir (RTG)-containing regimen. Of the mutations selected by DTG in vitro, S153FY was not detected in any isolate while L101I and T124A were highly prevalent in both groups and significantly associated with non-B subtype. RTG-selected double and triple mutants, mostly the G140S/Q148H variant, were detected in only 32 (26.7%) RTG-treated patients. As L101I and T124A do not appear to exert any major effect in vivo and double and triple mutants resistant to DTG are infrequently selected by RTG, DTG can be effectively used in INI-naïve patients and may retain activity in many patients failing RTG., (© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.)
- Published
- 2012
- Full Text
- View/download PDF
10. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens.
- Author
-
Marconi A, Balestrieri M, Comastri G, Pulvirenti FR, Gennari W, Tagliazucchi S, Pecorari M, Borghi V, Marri D, and Zazzi M
- Subjects
- Anti-Retroviral Agents therapeutic use, HIV Infections drug therapy, HIV-1 genetics, Humans, Linear Models, Reproducibility of Results, Sensitivity and Specificity, HIV Infections virology, RNA, Viral analysis, Specimen Handling methods, Viral Load methods
- Abstract
The Abbott Real-Time HIV-1 assay was evaluated for its performance in quantification of human immunodeficiency virus type 1 (HIV-1) RNA in dried blood spot (DBS) samples. In total, 169 blood samples with detectable plasma HIV-1 RNA were used to extract RNA from paired DBS and liquid plasma samples, using the automated Abbott m Sample Preparation System (m2000sp). HIV-1 RNA was then quantitated by the m2000rt RealTime analyser. RNA samples suitable for real-time PCR were obtained from all but one (99.4%) of the DBS samples and HIV-1 RNA was detected in 163/168 (97.0%) samples. The correlation between HIV-1 RNA values measured in paired DBS and plasma samples was very high (r = 0.882), with 78.5% and 99.4% of cases differing by <0.5 and 1.0 log, respectively. Retesting of DBS replicates following 6 months of storage at 2-8 degrees C showed no loss of HIV-1 RNA in a subset of 89 samples. The feasibility of DBS testing coupled with automated sample processing, and the use of a latest-generation FDA-approved real-time PCR-based system, represents an encouraging first step for viral load measurement in reference centres in developing countries where access to antiretroviral therapy is expanding.
- Published
- 2009
- Full Text
- View/download PDF
11. Follicular development and plasma concentrations of LH and prolactin in anestrous female dogs treated with the dopamine agonist cabergoline.
- Author
-
Spattini G, Borghi V, Thuróczy J, Balogh L, Scaramuzzi RJ, and De Rensis F
- Subjects
- Anestrus blood, Animals, Cabergoline, Dogs, Dopamine Agonists therapeutic use, Female, Ovarian Follicle physiology, Ovulation Induction methods, Anestrus drug effects, Ergolines therapeutic use, Luteinizing Hormone blood, Ovarian Follicle cytology, Ovarian Follicle drug effects, Ovulation Induction veterinary, Prolactin blood
- Abstract
The effect of a daily administration of a dopamine agonist (cabergoline, 5 microg/kg) for 4 weeks, starting about 95 days after the end of estrus on follicular development and its relationship with LH and prolactin secretion has been investigated in two groups of anestrous bitches (Beagles and Greyhounds). Pro-estrus was detected in 80% (8/10) of beagles and 50% (3/6) of treated greyhounds. The mean inter-estrus interval of treated animals was 132+/-5.0 and 169+/-7.0 days for beagles and greyhounds, respectively, and in both this differed significantly from the cycle preceding treatment (192+/-9.0 and 198+/-12.0 days) and from that in untreated bitches (194+/-11.0 and 196+/-11.0 days for beagles and greyhounds, respectively (all comparisons at P<0.001). The interval from the beginning of treatment to pro-estrus in responding animals was 13.3+/-1.90 days in beagles and 20.3+/-1.70 days in greyhounds. Cabergoline increased (P<0.001) the length of pro-estrus (10.6+/-0.50 and 11.7+/-0.50 days) in the treated estrus cycle compared to the previous estrus cycle (8.4+/-0.30 and 8.8+/-0.40 days for in beagles and greyhound, respectively). Ovarian enlargement and follicle development was detected by ultrasound in 90% of treated beagles and in 83% of greyhound between the second and third weeks of treatment, but only 80% of beagles and 66% of treated greyhound displayed pro-estrus and estrus. In the treated bitches, mean plasma LH increased (P<0.001) before pro-estrus. There was high variability in mean plasma prolactin levels between animals. These data indicate that the administration of the dopamine agonist cabergoline to anestrous bitches increases mean LH plasma levels and induces follicular development shortly before pro-estrus but this activity is not always followed by pro-estrus and estrus. Finally, prolactin per se does not have a prominent role in the control of folliculogenesis in the bitch.
- Published
- 2007
- Full Text
- View/download PDF
12. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
- Author
-
Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M, Borghi V, Rumpianesi F, Barchiesi F, and Esposito R
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Candida classification, Candida isolation & purification, Candidiasis microbiology, Candidiasis mortality, Child, Child, Preschool, Cross Infection epidemiology, Cross Infection microbiology, Drug Resistance, Fungal, Female, Fungemia microbiology, Fungemia mortality, Humans, Infant, Infant, Newborn, Italy epidemiology, Male, Microbial Sensitivity Tests, Middle Aged, Prevalence, Triazoles pharmacology, Antifungal Agents pharmacology, Candida drug effects, Candidiasis epidemiology, Fungemia epidemiology, Hospitals, University
- Abstract
The epidemiological and antifungal susceptibility data for 94 episodes of candidaemia in an Italian tertiary-care hospital between January 2000 and August 2003 were evaluated by prospective laboratory-based surveillance. The incidence of fungaemia was 0.90 episodes/10 000 patient-days, and the most common species isolated were Candida albicans (40.4%), Candida parapsilosis (22.3%), Candida tropicalis (16.0%) and Candida glabrata (12.8%). Among 24 patients who received antifungal prophylaxis, non-albicans Candida spp. were more prevalent than C. albicans (p 0.012). The 30-day mortality rate was high (38.2%), particularly for haematological (71.4%) and solid-organ transplant patients (50.0%), and in individuals with C. tropicalis and C. glabrata bloodstream infections (60.0% and 50.0%, respectively). In-vitro susceptibility tests demonstrated that 95% of the isolates were susceptible to amphotericin B (MIC < 2 mg/L), 98.1% to posaconazole (MIC < 1 mg/L), 95.8% to flucytosine (MIC < 32 mg/L) and fluconazole (MIC < 64 mg/L), and 94.7% to itraconazole (MIC < 1 mg/L). Posaconazole was active (MIC 0.5 mg/L) against all three isolates of Candida krusei, which had reduced susceptibility to both fluconazole and itraconazole. Overall, non-albicans Candida spp. accounted for 60% of the episodes of candidaemia, which could be related to the use of antifungal prophylaxis. Resistance is still uncommon in Candida spp. recovered from blood cultures. The in-vitro activity of posaconazole is encouraging, and this agent could play an important role in the management of invasive candidiasis, including episodes caused by inherently less susceptible species such as C. krusei.
- Published
- 2006
- Full Text
- View/download PDF
13. Evaluation of a sensitive and specific radioimmunoassay for pancreatic glucagon in human plasma and its clinical application.
- Author
-
Borghi VC, Wajchenberg BL, and Albuquerque RH
- Subjects
- Acromegaly blood, Adolescent, Adult, Arginine pharmacology, Cushing Syndrome blood, Diabetes Mellitus blood, Diabetes Mellitus, Type 1 blood, Female, Glucose Tolerance Test, Humans, Male, Middle Aged, Obesity blood, Glucagon blood, Radioimmunoassay methods
- Abstract
A glucagon radioimmunoassay employing antiserum specific for pancreatic glucagon is described. Glucagon was radioiodinated by the chloramine T technique and purified on QAE-Sephadex A 25 to a specific activity of 225 mu Ci/microgram. The standard curve allowed measurements from 12 to 500 pg/ml with sensitivity of 17.5 pg/ml, precision of 6.3-14.9% (CV, within-assay) and 5.6-10.7% (CV, between-assay). Recovery was between 82 and 112%. Fasting plasma glucagon levels in diabetics, obese subjects, acromegalics and patients with Cushing's syndrome were greater than in normals (22.0 +/- 91 pg/ml; mean +/- SD). Very low glucagon levels after oral glucose suppression (15.2 +/- 3.1 pg/ml) in normals and greatly increased values after arginine in insulin-dependent diabetics (271.0 +/- 132.3 pg/ml) could be determined.
- Published
- 1984
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.